Microfluidics laboratory

Microfluidics deals with the behaviour, precise control and manipulation of fluids that are geometrically constrained to a small, typically sub-millimeter, scale. It is a multidisciplinary field at the intersection of engineering, physics, chemistry, biochemistry, nanotechnology, and biotechnology, with practical applications in the design of systems in which low volumes of fluids are processed to achieve multiplexing, automation, and high-throughput screening. Microfluidics emerged in the beginning of the 1980s and is used in the development of inkjet printheads, DNA chips, lab-on-a-chip technology, micro-propulsion, and micro-thermal technologies.

Typically, micro means one of the following features:

  • small volumes (μL, nL, pL, fL)
  • small size
  • low energy consumption
  • effects of the microdomain

Typically fluids are moved, mixed, separated or otherwise processed. Numerous applications employ passive fluid control techniques like capillary forces. In some applications, external actuation means are additionally used for a directed transport of the media. Examples are rotary drives applying centrifugal forces for the fluid transport on the passive chips. Active microfluidics refers to the defined manipulation of the working fluid by active (micro) components such as micropumps or microvalves. Micropumps supply fluids in a continuous manner or are used for dosing. Microvalves determine the flow direction or the mode of movement of pumped liquids. Often processes which are normally carried out in a lab are miniaturised on a single chip in order to enhance efficiency and mobility as well as reducing sample and reagent volumes.

from https://en.wikipedia.org


  • Generation of innovative Biochips for biomedical applications by building a solid collaboration between European cell biologist and European nano-engineers.
  • Improved capability to control in-vitro co-culture parameters (cellular, physical, chemical).
  • Reconstitution of in-vitro environment mimicking in-vivo situations.
  • Reduction of animal experimentation.
  • Implementation of solutions for high-throughput drug screenings and personalize medicine
  • Creation of primary-cells-compliant environments for personalized medicine
  • Transfer of our technology to the market (academic laboratories, biotech, pharma, etc) by involving private companies since the very early stages of their conceptions.